CN Patent

CN102459172A — 四环化合物

Assigned to Chugai Pharmaceutical Co Ltd · Expires 2012-05-16 · 14y expired

What this patent protects

本发明提供一种含有ALK抑制化合物且能有效治疗和预防伴随有ALK异常的疾病，例如癌、癌转移、抑郁症或认知功能障碍的治疗和预防药。上述课题，通过含有下列通式(I)所示的化合物、其盐或者它们的溶剂化物的医药组合物来实现，其中，式中的标记，参考说明书中的定义。

USPTO Abstract

本发明提供一种含有ALK抑制化合物且能有效治疗和预防伴随有ALK异常的疾病，例如癌、癌转移、抑郁症或认知功能障碍的治疗和预防药。上述课题，通过含有下列通式(I)所示的化合物、其盐或者它们的溶剂化物的医药组合物来实现，其中，式中的标记，参考说明书中的定义。

Drugs covered by this patent

alectinib-hydrochloride (ALECTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN102459172A
Jurisdiction: CN
Classification: —
Expires: 2012-05-16
Drug substance claim: No
Drug product claim: No
Assignee: Chugai Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.